Rodent models of the human acetylation polymorphism: Comparisons of recombinant acetyltransferases

DeLeon, J.H., K.J. Martell, K.P. Vatsis and W.W. Weber (1995) Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). Drug Metab. Dispos., 23, 1354–1361. Doll, M.A., Y. Feng and D.W. Hein (1995) Cloning, sequencing, and functional characterization of NAT2*21B: A second polymorphic N-acetyltransferase gene identified in a slow acetylator rat. Abstracts of the VII Inter. Cong. Toxicol., Seattle, WA, 46–P–21. Doll, M.A. and D.W. Hein (1995) Cloning, sequencing, and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Pharmacogenetics, 5, 247–251. Ebisawa, T., Y. Sasaki and T. Deguchi (1995) Complimentary DNAs for two arylamine N-acetyltransferases with identical 5′-non-coding regions from rat pineal gland. Eur. J. Biochem., 228, 129–137. Feng, Y., R.J. Wagner, A.J. Fretland, W.K. Becker, A.M. Cooley, T.P. Pretlow, K.J. Lee and D.W. Hein (1996). Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2′-dimethyl-4-aminobiphenyl. Cancer Res., 56, 527–531. Ferguson, R.J., M.A. Doll, B.R. Baumstark and D.W. Hein (1994a) Polymorphic arylamine N-acetyltransferase encoding gene (NAT2) from homozygous rapid and slow acetylator congenic Syrian hamsters. Gene, 140, 247–249. Ferguson, R.J., M.A. Doll, T.D. Rustan, B.R. Baumstark and D.W. Hein (1994b) Syrian hamster monomorphic N-acetyltransferase (NAT1) alleles: amplification, cloning, sequencing, and expression in E. coli. Pharmacogenetics, 4, 82–90. Ferguson, R.J., M.A. Doll, T.D. Rustan and D.W. Hein (1996) Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the Syrian hamster. Pharmacogenetics, 6, 55–66. Fretland, A.J., M.A. Doll, K. Gray, Y. Feng and D.W. Hein (1996) Cloning, sequencing, and expression of NAT1 and NAT2 derived from C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse strains. The FASEB J., 10, A456. Glowinski, I.B. and W.W. Weber (1982) Genetic regulation of aromatic amine N-acetylation in inbred mice. J. Biol. Chem., 257, 1424–1430. Gray, K., M.A. Doll, R.J. Ferguson, T.D. Rustan and D.W. Hein (1996) Intrinsic stability comparisons between human, mouse, rat, and Syrian hamster recombinant N-acetyltransferases. The FASEB J., 10, A456. Hein, D.W. (1988) Acetylator genotype and arylamine-induced carcinogenesis. Biochim. Biophys. Acta, 948, 37–66. Hein, D.W. (1991) A new model for toxic risk assessments: Construction of homozygous rapid and slow acetylator congenic Syrian hamster lines. Toxicol. Meth., 1, 44–52. Hein, D.W., M.A. Doll, K. Gray, T.D. Rustan and R.J. Ferguson (1993) Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res., 53, 509–514. Hein, D.W., M.A. Doll, T.D. Rustan, K. Gray, R.J. Ferguson and Y. Feng (1994) Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol., 124, 16–24. Hein, D.W., M.A. Doll, T.D. Rustan and R.J. Ferguson (1995) Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific nucleic acid substitutions. Cancer Res., 55, 3531–3536. Hein, D.W., J.G. Omichinski, J.A. Brewer and W.W. Weber (1982) A unique pharmacogenetic expression of the N-acetylation polymorphism in the inbred hamster. J. Pharmacol. Exp. Ther., 220, 8–15. Hein, D.W., T.D. Rustan, K.D. Bucher, E.J. Furman and W.J. Martin (1991a) Extrahepatic expression of the N-acetylation polymorphism towards arylamine carcinogens in tumor target organs of an inbred rat model. J. Pharmacol. Exp. Ther., 258, 232–236. Hein, D.W., T.D. Rustan, K.D. Bucher, W.J. Martin and E.J. Furman (1991b) Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver. Drug Metab. Dispos., 19, 933–937. Juberg, D.R., J.T. Bond and W.W. Weber (1991) N-acetylation of aromatic amines: genetic polymorphism in inbred rat strains. Pharmacogenetics, 1, 50–57. Kelly, S.L. and E. Sim (1994) Arylamine N-acetyltransferase in Balb/c mice: Identification of a novel mouse isozyme by cloning and expression in vitro. Biochem. J., 302, 347–353. Land, S.J. (1993) Characterization of rat hepatic acetyltransferase. Ph.D. Dissertation, Wayne State University, Detroit. Land, S.J., R.F. Jones and C.M. King (1994) Biochemical and genetic analysis of two acetyltransferases from hamster tissues that can metabolize aromatic amine derivatives. Carcinogenesis, 15, 1585–1595. Mattano, S.S., R.P. Erickson, M.N. Nesbitt and W.W. Weber (1988) Linkage of Nat and ES-1 in the mouse and development of strains congenic for N-acetyltransferase. J. Hered., 79, 430–433. Martell, K.J., K.P. Vatsis and W.W. Weber (1991) Molecular genetic basis of rapid and slow acetylation in mice. Mol. Pharmacol., 40, 218–227. Nagata, K., S. Ozawa, M. Miyata, M. Shimada, Y. Yamazoe and R. Kato (1994) Primary structure and molecular basis of polymorphic appearance of an acetyltransferase (AT-II) in hamsters. Pharmacogenetics, 4, 91–100. Paulsen, J.E., I.-L. Steffensen, E. Namork, D.W. Hein and J. Alexander (1996) Effect of acetylator genotype on 3,2′-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Carcinogenesis, 17, 459–465. Tannen, R.H. and W.W. Weber (1980) Inheritance of acetylator phenotype in mice. J. Pharmacol. Exp. Ther., 213, 480–484. Vatsis, K.P., W.W. Weber, D.A. Bell, Dupret, J.-M., D.A. Price-Evans, D.M. Grant, D.W. Hein, H.J. Lin, U.A. Meyer, M.V. Relling, E. Sim, T. Suzuki and Y. Yamazoe (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics, 5, 1–17. Weber, W.W. and D.W. Hein (1985) N-acetylation pharmacogenetics. Pharmacol. Rev., 37, 25–79.